M2Gen® is a health informatics solutions company focused on accelerating the discovery, development and delivery of personalized medicine. Our Company was founded in 2006 at the Moffitt Cancer Center to operationalize the Total Cancer Care® Protocol, a unique approach to studying patients throughout their lifetime. In this effort, we partner with the nation’s leading cancer centers via the Oncology Research Information Exchange Network (ORIEN).
Total Cancer Care®is one the world’s largest observational research studies in cancer. TCC represents a true partnership with patients who donate their clinical data and tissue so that we may learn from their experiences and develop evidence-based approaches to meet their needs. Consented patients agree to be contacted for future studies, playing an active role in the study of their cancer and improving care for future generations.
The Oncology Research Information Exchange Network ( ORIEN) is a unique research partnership among the nation’s leading cancer centers that recognize collaboration and access to data are the keys to advancing cancer discovery, and delivering improved cancer care. Members agree to use the Total Cancer Care protocol and share data to advance the discovery and development of new therapies.
M2Gen provides informatics-based solutions to accelerate the discovery, development and delivery of personalized medicine.
Using the information learned from patients through the Total Cancer Care® Protocol, and in partnership with our ORIEN Members, we work with biopharmaceutical companies to address the most challenging questions in drug development. Total Cancer Care provides a harmonized approach to link longitudinal clinical data with molecular information, enabling a much deeper understanding of a patient’s disease. This “opt-in” approach allows for patients to be re-contacted for further studies, creating an information-driven ecosystem to accelerate cancer research.
Our core solution, ORIEN Avatar TM is a pre-competitive informatics environment featuring a robust integrated clinical and molecular dataset combined with proprietary software tools to power discovery and development. We also work with leading biopharmaceutical companies on projects featuring informatics-based approaches to target and biomarker discovery, trial design and enrollment and post-market analysis.
Founder and Executive Chair of M2Gen
Dr. William (Bill) S. Dalton is Founder and Executive Chair. He is the former CEO of M2Gen (2012-2017) and past President, CEO & Center Director of Moffitt Cancer Center, an NCI-Designated Comprehensive Cancer Center (2002-2012). During his tenure as CEO of Moffitt, he led the development of the Total Cancer Care program and creation of the Health Research Informatics platform designed to follow patients throughout their lifetime. He holds several patents in the area of personalized medicine and computer networking. In 2014, Moffitt Cancer Center, in partnership with the James Cancer Center at the Ohio State University, founded the cancer center alliance called ORIEN, Oncology Research Information and Exchange Network, with the goal of accelerating cancer research discovery by sharing information and delivering hope through collaborative learning and partnerships.
President and CEO of M2Gen
Timothy R. Wright is the President and CEO of M2Gen®. He was previously the Executive Vice President, Business Development, Strategy and Innovation at Teva. Mr. Wright is the founder and Chairman of the Drug Discovery and Development Institute for The Ohio State University Comprehensive Cancer Center, where he previously served as Director. He is a current a member of the Ohio State Innovation Foundation Board and the Ohio State School of Pharmacy External Advisory Board. Mr. Wright has served in executive leadership roles at several pharmaceutical firms, including Covidien, Elan, and DuPont Merck. He holds a B.Sc. from The Ohio State University.
Chief Scientific/Bioinformatics Officer of M2Gen
Hongyue Dai, PhD, currently serves as M2Gen’s Chief Bioinformatics Officer / Chief Scientific Officer. In his role, he works with clients to understand their questions about biomarkers and patient populations, and develop novel solutions that add value and bring more effective, targeted drugs to right cancer patients sooner. Dr. Dai has over 15 years of data analysis experience in pharma and biotech, most recently as Executive Director, Informatics & Analysis at Merck Research Lab leading a group of 50 scientists. He has worked extensively on the analysis of genomic and genetic data to identify and validate novel drug targets and biomarkers, and to understand disease progression, mechanisms of compounds. He also has a strong publication record, including papers in Nature, Science and Cell.
Senior Vice President, Chief Financial Officer of M2Gen
Joseph R. Smith, CPA, CGMA, currently serves as the Senior Vice President and Chief Financial Officer for M2Gen, a wholly owned for profit subsidiary of Moffitt Cancer Center. In this role, Joe is responsible for the financial, marketing and sales aspects of M2Gen and provides leadership for the day to day financial and operational aspects of the business. Prior to joining M2Gen Joe served as Chief Operating Officer and Chief Financial Officer for Bisk Education and also was the CFO, Secretary and Treasurer for a private then public dental practice management company. Joe started his career in public accounting at Deloitte, rose to the level of Partner and was in charge of the middle market practice in the Tampa, Florida office. He holds a BSBA in Accounting with Honors from University of Florida.
VP/ Chief Administrative Officer of M2Gen
Administrator, Oncology Research Information Exchange Network (ORIEN)
Odalys Capote currently serves as Vice President/Chief Administrative Officer & Administrator for the Oncology Research Information Exchange Network (ORIEN) at M2Gen. She also serves as Administrator of the DeBartolo Family Personalized Medicine Institute at Moffitt Cancer Center. Odalys has over 30 years of experience in healthcare, including such roles as: Chief of Staff, Compliance & Privacy Officer, cost accounting/decision support implementation, project management and consulting. She holds a Bachelor’s degree in Marketing from the University of South Florida School of Business.
Vice President of Strategy and Business Development, M2Gen
Naveen Kumar currently serves as Vice President, Strategy and Business Development for M2Gen, and is primarily responsible for supporting M2Gen’s growth through partnership with life science and technology companies, as well as cancer centers via ORIEN. Prior to joining M2Gen, Naveen held various management consulting and financial advisory roles serving the health care industry. He holds a B.A, with Honors, from New York University and a M.Sc. in Finance and Economics from the London School of Economics.
Vice President of Medical Informatics, M2Gen
Judy Barkal currently serves as the Vice President of Medical Informatics at M2Gen. She brings deep experience in strategy, innovation and complex business and technology transformation. Judy’s most recent role was Head of Information Strategy and Innovation at Knight Cancer Institute, Oregon Health and Science University. At OHSU, Judy established a cancer informatics strategic roadmap and, as PI, led the creation of a clinical data repository integrated with genomics data to serve multiple cancer researchers and programs. Judy was previously a Partner at IBM, Global Business Services where she led complex business and technology transformations globally in financial services, healthcare, energy, and retail. Prior to IBM, Judy specialized in clusters and high performance computing at Sequent Computer Systems. In her early career, she developed safety-critical, real-time flight control systems at Rockwell Collins.
Vice President and Chief Commercial Officer, M2Gen
Stan brings to M2Gen significant life sciences experience, including leadership roles within multiple aspects of the branded and generic pharmaceutical product value chain, new business ventures and negotiation of several, large corporate transactions.
Prior to joining M2Gen, Stan served as the Director, Oncology Commercialization at The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute (OSUCCC – James). From 2014 to 2016, Stan was the Director of Licensing for The Ohio State University’s (OSU) Technology Commercialization Office. Prior to joining OSU, Stan held executive roles within two mid-sized pharmaceutical companies (Xanodyne Pharmaceuticals and AAIPharma) leading their corporate/ business development functions, specifically in- and out- licensing, acquisitions and divestitures.
For over 19 years at Abbott Laboratories he held positions of increasing responsibility in several functional areas, including national account sales, marketing, business development and licensing, engineering and international manufacturing/ operations.
Stan earned his B.Sc. in Chemical Engineering from the Illinois Institute of Technology in Chicago and his MBA in Marketing and International Management from Northwestern University’s Kellogg Graduate School of Management in Evanston, IL.
Senior Vice President, Chief Legal & Development Officer - Hearst
James M. Asher is senior vice president and chief legal and development officer of Hearst. He joined Hearst in October 1997. He is a member of the board of directors of Hearst and Fitch Group, and is a testamentary trustee under the will of William Randolph Hearst. Previously, he served as managing partner and chairman of the executive committee of Rogers & Wells, an international law firm.
As chief legal officer, Asher has general responsibility for all of Hearst's legal affairs. As chief development officer, he is engaged with Hearst's senior operating management in new ventures, acquisitions and internal business development efforts
Asher joined Rogers & Wells in 1974 after graduating from New York University School of Law with a J.D. degree. He was named a partner of the law firm in 1981, was appointed the firm's managing partner in 1990 and became chairman of the executive committee in 1994.
Director, The Ohio State University Comprehensive Cancer Center Kathleen Wellenreiter Klotz Chair in Cancer Research
Raphael E. Pollock, MD, PhD was born in Chicago, IL in 1950; he is a graduate of Oberlin College, Oberlin, OH, where he majored in history. This was followed by medical school at St. Louis University, St. Louis, MO, residency training in general surgery at Rush-Presbyterian- St. Luke’s Medical Center and the University of Chicago Hospitals and Clinics, Chicago, IL, followed by fellowship training in surgical oncology at the University of Texas MD Anderson Cancer Center, Houston, TX. Dr. Pollock was invited to join the MD Anderson faculty in 1984 upon completion of fellowship training. While serving as an assistant professor of surgery, Dr. Pollock began graduate studies at the University of Texas Health Science Center/Houston, Graduate School of Biomedical Sciences, culminating in receipt of the PhD in tumor immunology in 1990. In 1993 Dr. Pollock began service as Chairman of the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center, a position that he held until 2010. In 1996, service as Head of the Division of Surgery at the University of Texas MD Anderson Cancer Center was begun, a position entailing supervisory relationships with all seven surgical specialty departments at that institution. In 2013 Dr. Pollock was recruited to The Ohio State University as Professor and Director of the Division of Surgical Oncology and Chief of Surgical Services at the James Comprehensive Cancer Center. This was followed by appointment in 2015 as Surgeon in Chief, the James Comprehensive Cancer Center and Surgeon in Chief, The Ohio State University Health System. In 2017, Dr. Pollock was appointed to his current position as Professor and Director, The Ohio State University Comprehensive Cancer Center.
Dr. Pollock’s clinical and laboratory research work focuses on soft tissue sarcoma, a rare tumor system of connective tissue origin. He has been the recipient as principal investigator of an NIH/NCI K08 Clinician-Investigator Award (1984-89), an NIH/NCI R29 FIRST Award (1989-1994), an NIH/NCI R01 Award (1995-2007), and NIH/NCI T32 Training Grant (1999-2010), and an NIH/NCI SPORE award (2012-2017). He is married to Dina Lev, MD, a Professor of Surgery at Tel Aviv University Sackler School of Medicine, Tel Aviv, Israel. They have five children: Jessica, a medical student at The Ohio State University College of Medicine, Samuel and Eden, students at The Ohio State University College of Arts and Sciences, and Noam and Omer, who are in high school in Tel Aviv, Israel.
President - Premium Mortgage, Inc.
Ted Couch, Sr. was born October 24th, 1936 in Tampa, Florida. He graduated from Jesuit High School in 1954, entered a Roman Catholic Seminary for one year and thereafter attended the University of Tampa and the Louisiana State University School of Banking
His full time working career began in 1956 with the newly formed First Industrial Savings Bank of Tampa where he was employed as a runner. In 1958, First Industrial became the Northside Bank of Tampa and moved to a North Tampa location as a full commercial bank. By this time Mr. Couch had worked his way up to becoming an officer of the bank and after holding every office position in the bank in 1966 he earned the title of President. In 1977, Mr. Couch left the bank to pursue the development of commercial real estate in the North Tampa area. Currently, he is President of Premium Mortgage, Inc., an asset based lender established in 1956.
In 1981 Mr. Couch and his partner George Cortner agreed to fund a chair in cancer research at the University of South Florida. This financial support from the community assisted in the appropriation of funding by the Legislature and through the persistence of the House Speaker, H. Lee Moffitt, the Moffitt Cancer and Research Center on the campus of USF became a reality. Mr. Couch chaired the board of directors of the Moffitt Cancer Center for 7 years. In the year 2000, he stepped down to chair Moffitt’s first capital campaign. This ambitious effort concluded in 2006 after exceeding the $87 million goal. In 2007, he became Chairman of M2Gen, Inc. a subsidiary of the H. Lee Moffitt Cancer Center and is now Chair Emeritus.
During his working career Mr. Couch has chaired the University Community Hospital Board and is now emeritus after 27 years of service. He has served on numerous boards and foundations in the community and has been a consistent donor to countless charities in the Tampa Bay Community.
He maintains that wealth demands increased responsibility along with personal discipline and wealth does not bring happiness to a person’s life but sharing of wealth does.
Executive Chair of the Board - M2Gen
Dr. William (Bill) Dalton serves as Executive Chair of the Board, of M2Gen, a health informatics solutions company, focused on accelerating the discovery, development and delivery of personalized medicine. He was the President and CEO of Moffitt Cancer Center from 2002 to 2012, and CEO of M2Gen from 2012 to 2017. He is interested in the development of personalized cancer care and patient-centered outcomes research and developing evidence-based, personalized cancer treatments and information/decision tools for patients and clinicians. In 2014, the Moffitt Cancer Center, in partnership with the James Cancer Center at the Ohio State University, founded the cancer center alliance called ORIEN, Oncology Research Information and Exchange Network, with the goal of accelerating cancer research discovery by sharing information and delivering hope through collaborative learning and partnerships. There are currently seventeen cancer centers that have joined ORIEN. Dr. Dalton is the past-Chair of the Personalized Medicine Coalition and current Chair of the Institute of Human and Machine Cognition. He has over 200 publications and has numerous patents in the fields of drug discovery and computer/information networking. He was elected into the Florida Inventors Hall of Fame in 2016.
President - Hearst Health
Greg Dorn is the president of Hearst Health, overseeing FDB (First Databank), Zynx Health, MCG and Hearst Health International; and serving as a director of Homecare Homebase MedHOK, M2Gen, Hearst Health Ventures and the Hearst Health Innovation Lab.
The mission of the Hearst Health network is to help guide the most important care moments by delivering vital information into the hands of everyone who touches a person’s health journey. Each year in the U.S., care guidance from the Hearst Health network reaches 84 percent of discharged patients, 177 million insured individuals, 60 million home health visits and 3.1 billion dispensed prescriptions.
For more than two decades, Dorn has been focused on raising the standard of excellence for patient care across the healthcare spectrum, through clinically rigorous guidance delivered by efficient, scalable technology. He is the co-inventor of two patented healthcare software technologies that continue to be used in health systems across the U.S. His expertise is in developing and commercializing inventive and disruptive solutions that improve care quality and efficiency.
Dorn has held a variety of leadership positions across Hearst, including chief operating officer of Zynx Health and president of FDB. In 2013 he was appointed an executive vice president of Hearst Business Media, and continues to serve in that role. He is also a vice president of Hearst.
Dorn received his medical doctorate from the Columbia University College of Physicians and Surgeons and his bachelor's degree from the Columbia University School of Engineering. He performed his clinical training at UCLA, where he also obtained his master’s degree in health services management.
President and CEO - Moffitt Cancer Center
Dr. Alan List is the President and Chief Executive Officer of Moffitt Cancer Center in Tampa, FL.
Dr. List is internationally recognized for his many contributions in the development of novel, more effective treatment strategies for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). His pioneering work led to the development of lenalidomide (Revlimid®) from the laboratory to clinical trials, which went on to receive fast-track designation from the U.S. Food and Drug Administration and approval for the treatment of patients with MDS and multiple myeloma. This work transformed the natural history of MDS from a premalignant condition that progressed to malignancy requiring aggressive treatment to a condition managed in the outpatient setting with oral agents.
Prior to his current position, Dr. List served as Executive Vice President and Physician-in-Chief, the Vice Deputy Physician-in-Chief, and the Chief of the Malignant Hematology Division at Moffitt, where he holds the Morsani Endowed Chair.
Before coming to Moffitt in 2003, Dr. List was a Professor of Medicine at the University of Arizona, Tucson, where he also served concurrently as the Director of the Leukemia and Blood and Marrow Transplant Program and Director of the Division of Translational/Clinical Research Program.
After earning a medical degree in 1980 from the University of Pennsylvania, Philadelphia, Dr. List completed an internship and residency in internal medicine at the Good Samaritan Medical Center in Phoenix, Arizona. He then completed fellowships in hematology and medical oncology at Vanderbilt University Medical Center in Nashville, Tennessee.
Dr. List has received peer-reviewed NIH support for his work and publishes extensively in the areas of MDS and acute leukemia, authoring more than 350 peer-reviewed manuscripts, chapters, and books. He lectures nationally and internationally and has received several awards in recognition of his seminal contributions such as the Aplastic Anemia & MDS International Foundation Leadership in Science Award (2014); induction into The Joshua Lederberg Society (2009); the Emil J. Freireich Award for Clinical Research, M.D. Anderson (2006); the J.P. McCarthy International Prize for Advancing the Body of Scientific Knowledge in Myelodysplastic Syndrome (2004); and the General Motors Cancer Research Foundation Merit Award (1991).
He serves as a member of the Myelodysplastic Syndrome Foundation Board of Directors and is the President-elect (2017-18) for the Society of Hematologic Oncology. He also is an active member of the American Society of Clinical Oncology; American Society of Hematology; American Association for Cancer Research; and the Southwestern Oncology Group.
Chairman Emeritus - Liberty Partners Group, LLC
Senator Connie Mack represented the State of Florida in the United States Congress for 18 years, including 12 years in the United States Senate where he played a leading role in economic and health care issues. At the time of his retirement in 2001, Senator Mack served as the Republican Conference Chairman, making him the third-ranking member of the Senate Republican leadership.
Senator Mack became the first Republican in Florida history to be re-elected to the U.S. Senate in 1994 when he received more than 70 percent of the vote, more than any other Republican candidate in the nation. Prior to his election to the Senate, he served three two-year terms as a member of the House of Representatives from southwest Florida. In April 1994, Mack was named by Campaign and Elections magazine as one of the 20 most popular elected officials in America. As a House member, U.S. News and World Report identified him as one of the nation’s most effective “new rising political stars.” In 1996, Mack was considered by Republican presidential candidate Bob Dole to serve as his vice-presidential running mate.
For the past 10 years, Senator Mack has worked with clients to develop and implement strategies to successfully achieve their legislative policy goals. In 2007, he became a founding Partner and Senior Policy Advisor with Liberty Partners of Florida, LLC in Tallahassee and continued in these roles as the partnership expanded in January 2010 into Liberty Partners Group, LLC in Washington, DC which focuses on advocacy strategies at the state and federal levels of government. Appointed by President Bush in 2005, Senator Mack served as Chairman of the President’s Advisory Panel for Federal Tax Reform. Senator Mack serves as Chairman Emeritus of Liberty Partners Group, is a member of the Board of Directors of M2Gen, H. Lee Moffitt Cancer Center & Research Institute in Tampa, Fl, and Mutual of America Life Company.
President - Hearst Business Media
Richard P. Malloch is the president of Hearst Business Media. He joined Hearst in 1991 as deputy group head of Hearst’s Consumer Book Publishing and Trade Magazine Group. In the late 1990s, Hearst sold the consumer book business (William Morrow and Avon Books) to HarperCollins. Malloch looked to reinvest the proceeds from the sale and build a fifth large operating group for Hearst. Traditionally, Hearst’s trade publishing was based on print products with significant revenue generated from advertising. Malloch changed the strategy and business model, moving the Group toward revenue generated from subscriptions and licensing fees. In consideration of this new strategy, the Group was renamed Hearst Business Media. Today, the business is nearly 100 percent digital.
In addition to his role as president of Hearst Business Media, Malloch is a senior vice president of Hearst and a member of the Board of Directors.
Hearst Business Media focuses on the financial, healthcare and transportation industries. Business Media wants to become indispensable to its customers. It enjoys very high (over 90 percent) renewal rates and has gained the confidence of many of its customers as seen by long-term (7- to 10-year) license agreements.
Hearst Business Media has shown substantial growth in the past 10 years. Internal growth and product enhancements have been coupled with acquisitions to make Business Media a significant contributor to Hearst’s financial performance. Hearst Business Media has become the second largest contributor to Hearst—contributing more operating income than the traditional consumer media businesses Hearst is best known for. Key investment acquisitions include: Fitch Group, CAMP Systems International, MedHOK, Homecare Homebase, MCG and Zynx Health.
Prior to joining Hearst, Malloch served as a principal in the New York office of Morgan Stanley & Co., where he was involved in corporate finance and merger and acquisitions. Malloch has devoted most of his professional life to working with companies in the communications and technology industries. He was actively involved in expanding the Morgan Stanley media franchise to include: cable television, cellular telephone, entertainment and information technologies. Malloch also helped to develop the media practice in Europe and Asia.
Malloch began his career as a member of the policy staff to the assistant secretary of the U.S. Department of Energy in Washington, D.C.
Co-Founder and Chief Executive Officer - Lumina Analytics
Allan S. Martin co-founded Lumina Analytics in 2015 and now serves as Chief Executive Officer for the company. Mr. Martin is also chairman of Atlantic Merchant Capital Investors, a private merchant bank in Tampa, Florida founded in 2009. Additionally, he is the managing partner of Fleur De Lis Partners.
Allan Martin is the Chairman of Moffitt Medical Group Board of Directors. Mr. Martin is also a trustee of Tampa Jesuit High School and is Chairman of the Martin Family Foundation. Prior to Lumina and Atlantic Merchant Capital Investors, Mr. Martin was Chief Executive Officer of MCS Holdings, the nation's second largest mortgage field services firm from 2003 to 2009. He was a founder and advisory board member of USAmeriBank from 2006 to 2010. Mr. Martin started his career with Deloitte & Touche following the receipt of a Bachelor of Science degree from the University of Southern Maine. Allan and his wife, Marie live in Tampa and have three children.
CEO - Black Diamond Capital Corporation
Bob Rothman is CEO of Black Diamond Group, Inc., a private investment company he founded in 1999. He is also co-owner and director of the Washington Redskins NFL franchise. From 1987 to 1999, Bob was chairman of the board and CEO of Consolidated International Group, Inc., which owned and operated insurance companies in Europe and North America. Bob is immediate past chair of Moffitt Cancer Center’s Institute Board (2008-2016) and continues to serve on the board. Since 1999, he has been a member of the Advisory Council of the University of Chicago, Booth School of Business. Bob earned his B.S. in Economics from Queens College of the City University of New York and an MBA in Finance from the University of Chicago Graduate School of Business.
Center Director & Executive Vice President - Moffitt Cancer Center & Research Institute
Dr. Sellers completed his undergraduate studies in community nutrition at the University of California Davis, his PhD in Epidemiology from Tulane University in 1988 and completed post doctorate training in statistical genetics training at Louisiana State University the following year. He then joined the University of Minnesota School of Public Health faculty, where he attained tenure and served as associate director of their cancer center. In 1998 he joined the Mayo Clinic Cancer Center. He served as deputy director from 2002 until he left to join Moffitt.
Dr. Thomas Sellers is Director of the Cancer Center and the Moffitt Research Institute and Executive Vice President. He previously served as Associate Center Director of Cancer Prevention & Control. He joined Moffitt in August 2003.
Studying the functional changes associated with cancer reflects the interaction of genetic and environmental factors. Dr. Sellers is using epidemiology and molecular genetics to sort out this complex interplay and inform better methods for prevention and clinical management.
Dr. Sellers is the author of more than 340 peer-reviewed original manuscripts that have been published in journals such as Cancer, New England Journal of Medicine, American Journal of Epidemiology, JAMA, Cancer Research and Nature Genetics. He has garnered more than $45M in grant support as principal or co-principal investigator from the National Cancer Institute. Dr. Sellers serves as a reviewer on several editorial boards including the Journal of Clinical Oncology, Frontiers in Applied Genetic Epidemiology and is deputy editor for Cancer Epidemiology Biomarkers and Prevention. Dr. Sellers has been invited to present at over 50 national and international events including Nijmegen, the Netherlands; Tianjin, China; Stockholm, Sweden; London, England, Heidelberg, Germany and Shanghai, China.
President and Chief Executive Officer - Hearst
Steven R. Swartz became president and chief executive officer of Hearst, one of the nation's largest diversified media, information and services companies, on June 1, 2013, having worked for the company for more than 20 years and served as its chief operating officer since 2011.
Hearst's major interests include ownership in cable television networks such as A&E, HISTORY, Lifetime and ESPN; majority ownership of global ratings agency Fitch Group; Hearst Health, a group of medical information and services businesses; 30 television stations such as WCVB in Boston and KCRA in Sacramento, Calif.; newspapers such as the Houston Chronicle, San Francisco Chronicle and Albany Times Union, more than 300 magazines around the world including Cosmopolitan, ELLE, Harper’s Bazaar and Car & Driver; digital services businesses such as iCrossing and KUBRA; and investments in emerging digital and video companies such as Verizon Hearst Media Partners, Complex, BuzzFeed, VICE and AwesomenessTV.
Swartz, 55, is a member of the Hearst board of directors, a trustee of the Hearst Family Trust and a director of the Hearst Foundations.
He was president of Hearst Newspapers from 2009 to 2011, and executive vice president from 2001 to 2008. From 1995 to 2000, Swartz was president and chief executive of SmartMoney, a magazine venture launched by Hearst and The Wall Street Journal in 1991 with Swartz as founding editor. Under his leadership, SmartMoney magazine won two National Magazine Awards and was Advertising Age’s Magazine of the Year.
Swartz began his career in 1984 as a reporter with The Wall Street Journal after graduating from Harvard. He served as an editor on the Journal's Page One staff from 1989 to 1991.
Swartz is chairman of the Associated Press and a member of the board of directors of ESPN and Lincoln Center for the Performing Arts, where he is also chairman of the Lincoln Center Corporate Fund and co-chairman of the Lincoln Center Business Advisory Council. He is a trustee of NewYork-Presbyterian Hospital, vice chairman of the Partnership for New York City and a member of the Business Roundtable.
President and Chief Executive Officer - M2GEN
Mr. Timothy R. Wright is the President and CEO of M2Gen®. Mr. Wright was previously the Executive Vice President, Business Development, Strategy and Innovation at Teva from 2015 to 2017. He is the founder and Chairman of the Drug Discovery and Development Institute for The Ohio State University Comprehensive Cancer Center, and served as a Director there from 2011 to 2015. He is currently a member of the Ohio State Innovation Foundation Board and the Ohio State School of Pharmacy External Advisory Board. Mr. Wright served as President of Covidien Pharmaceuticals from 2007 to 2010. From 2004 to 2007, he was CEO (Interim) & President, a member of the board of directors, and Chief Operating Officer at AAI Pharmaceuticals/Xanodyne. Mr. Wright served at Elan Bio-Pharmaceuticals as President, Global Operations from 2000 to 2004, and President, Europe, Japan & ROW and Executive Vice President, Business Development & Licensing from 2000 to 2002. During 1984 to 1999, he served at DuPont Merck Pharmaceutical Company, holding roles such as Senior Vice President, Strategy & Corporate Business Development from 1996 to 1999, Vice President, Strategic Marketing & Operations—Europe from 1995 to 1996, President & CEO, Toronto, Canada from 1993 to 1995, and Vice President, Marketing from 1990 to 1993. Mr. Wright holds a B.Sc. from The Ohio State University.